As a leader in the discovery and development of best-in-class therapeutic candidates with our RADS™ (RNA molecules with superior Activity, Durability, and Safety) siRNA platform, we collaborate with partners who share our commitment to advancing RNA-based medicines. Our proprietary siRNA platform technology, RADS, provides best-in-class candidates for a broad range of indications.

Through strategic partnerships, out-licensing opportunities, and asset acquisitions, Argo seeks to expedite the advancement of our novel therapies into clinical trials and, ultimately, to global markets for the benefit of patients. By combining our technology and expertise with that of our partners, we aim to bring innovative therapies to patients faster and more efficiently.

Our strategic collaboration with Novartis, a global therapeutic leader in the cardiovascular, renal and metabolic space, has yielded multi-asset license and option agreements to advance Argo’s novel molecules for the treatment of cardiovascular diseases.

To discuss business development opportunities, please contact us at BD@argobiopharma.com.